RxDoctor Payments Data

Cruz Fana Souchet, MD

Internal Medicine · Dunedin, FLNPI 1811050602

Payments from drug & device makers

$1,062in general payments, 2019–2025

Across 44 payments — averaging $24.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$243
  • AbbVie$189
  • GSK$181
  • Pfizer$125
  • Vertiflex, Inc.$112
  • Lilly USA, LLC$98
  • plus $113 from 5 others

What the payments were for

  • Food & beverage$1,062100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca14$243
AbbVie(2 entities)4$189
GSK8$181
Pfizer6$125
Vertiflex, Inc.1$112
Lilly USA, LLC5$98
Novo Nordisk2$47
Amarin Pharma, Inc.1$22
Lucid Diagnostics Inc.1$16
Metuchen Pharmaceuticals1$14
Fidia Pharma USA Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,062 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$29,960
Medicare patients
94
Services billed
384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$66,923
XareltoRivaroxaban47$53,886
ProliaDenosumab28$49,118
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$47,865
JulucaDolutegravir/Rilpivirine12$41,304
JardianceEmpagliflozin24$35,073
RybelsusSemaglutide23$34,420
OzempicSemaglutide29$28,719
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$23,504
Breo ElliptaFluticasone/Vilanterol17$15,249
MyrbetriqMirabegron13$13,685
FarxigaDapagliflozin Propanediol18$13,669
SymbicortBudesonide/Formoterol Fumarate28$12,861
CreonLipase/Protease/Amylase17$11,592
Fluticasone-SalmeterolFluticasone Propion/Salmeterol40$8,702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$125$66,92354 claims
Novo NordiskRybelsus, Ozempic$47$63,13952 claims
GSKTrelegy Ellipta, Breo Ellipta$181$63,11465 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$243$50,03577 claims
AbbVieCreon, Synthroid$189$14,49547 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Dunedin

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →